Rebeprazole sodium

Research use only, not for human use.

Rebeprazole sodium is a proton pump inhibitor.

Rebeprazole sodium is a proton pump inhibitor.(In Vitro):Rabeprazole attenuates the cell viability of the human gastric cancer cells following treatment with 0.2 mM for 16 hours.Rabeprazole completely inhibits the phosphorylation of ERK1/2 in the MKN-28 cells. The gastric cancer cell line MKN-28 is cultured in acidic culture media (pH 5.4) for 2 hours. Pretreatment with Rabeprazole (0.2 mM for 2 hours) leads to strong inhibition of ERK 1/2 phosphorylation in the MKN-28 cells.(In Vivo):Rabeprazole (10 mg/kg; P.O.; every 48 h for 18 weeks) course leads to a significant decline in bone mineral density (BMD) and decreases serum calcium level and produces secondary hyperparathyroidism in female mice.

——

Animal Model:Female Swiss albino mice (body weight equals 18-26 g)Dosage:10 mg/kg Administration:Oral administration; every 48 h for 18 weeksResult:Showed significantly lower serum calcium level compared to the vehicle treated group (5.5±2.07 vs. 9.68±2.77).

E 3810 | LY307640

Membrane Transporter/Ion Channel

Proton Pump

Proton pump

Inflammation/Immunology

——

117976-90-6

381.42

C18H20N3NaO3S

>98% (HPLC)

DMSO: 76mg/ml(199.26 mM);Water: 76mg/ml(199.26 mM);Ethanol: 76mg/ml(199.26 mM)

[Na+].COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1

sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide

(-20℃)

With Ice Pack

≥ 2 years